Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: even I was surprised

July 3, 2018 4:42pm

By the forward motion of the sector

Signing-off with a marinated olive in distilled spirits

Happy Fourth – be careful out there!

Pre-open indications: 1 HITs and 3 MISS (but the least, you sold into strength and have holiday slushy money)

It’s an honor to be considered the “canary in the (sectors) coal mine”! I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths.

RMi is the source investors and traders need – it’s more than opinion, the facts and truth need to be recognized!

Want to know WHY, subscribe!

Henry’omics:

Volume was LOW, except in AGTC (+$0.40) and MDXG (+$0.05) – both to the upside.

Feeling the downside spin was: KOOL -$0.0178), CLBS (-$0.08), CUR (-$0.01), RARE -$0.11), MESO, RENE.L (-$3.50), EDIT (-$0.17), VCEL (-$0.10) and BSTG (-$0.27 - my opinion, the next Theranos “story”)

From the pre-open newsletter titled …“thin trading? Mid-week holiday’s don’t set expectation but, do exasperate anticipation of what’s sustainable.”

I also stated, “It’s that time again, quarterly results are being prepared: loss per share (LPS), operational spending, ATM usage and the always lingering issues of stock-based compensation.”

Of the 45 companies covered on Tuesday; 9 downside equities finished in a range of -$0.01 (CUR) to -$1.50 (RENE.L) while the 33 upside equities oscillated from +$0.03 (ONVO) to $3.45 (BLUE)with 3 flat close.

MY working trend (5 largest) lines:

… The greatest volume to the downside: VCEL, EDIT, RARE, KOOL and CLLS

… Upside volume was weighted to: MDXG, VSTM, ADVM, GBT and SGMO

… Biggest $ downside: RENE.L (-$3.50), BSTG (-$0.27), MESO (-$0.18), EDIT (-$0.17) and RARE (-$0.11)

… Best moves to the $ upside: BLUE (+$3.45), RGNX (+$3.05), SLDB (+$2.86), GBT (+$2.05) and BLFS (+$1.71)

… Flats: ADRO, FIXX and PSTI

The weekly count - decliners versus gainers – new month:

……. look at the differences in decliners:

Tuesday’s decliners ranged from -0.14% <RARE -$0.11 > to -5.97% <BSTG -$0.27 > in 9 equities;
Monday’s decliners ranged from -0.20% <AXGN -$0.10> to -38.5% <MDXG -$2.46> in 15 equities;

Versus

… Look at the percentage’s (%) and spreads …

Tuesday’s gainers ranged from +0.55% < ALNY +$0.54> to +11.41% <BLFS +$1.71 > in 33 equities;
Monday’s gainers ranged from +0.04% <AST +$0.00> to +31.38% <BLFS +$3.58 > in 27 equities;

Daily analytics and metrics:

The Dow declined 132.36 points to close at 24,174.82
The S&P 500 fell 0.55 to 2,713.22.
The NASDAQ pulled back 0.95 to 7,502.67

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 24/17 and 4 flats;
The mid-day was positive with an A/DL of 35/7 and 3 flats;
The close was positive with an A/DL of 33/9 and 3 flat;

Pre-open indications: 1 hit and 3 miss

UniQure N.V. (QURE) closed up +$0.31 – miss;
CRISPR Therapeutics (CRSP) closed up +$1.21 – miss;
Intellia (NTLA) closed up +$0.84 – miss;
Editas Medicine (EDIT) closed down - $0.217 – hit;

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,

Tuesday traded at 16.14, up +3.46%
Monday traded at 15.6, down -3.05%

The iShares Russell 2000 (IWM) closed:

Tuesday was up +0.40%;
Monday was up +0.68%;

The iShares NASDAQ Biotechnology (IBB) closed:

Tuesday was down -0.09%
Monday was up +0.79%

JULY sessions:

Tuesday closed POSITIVE with 9 decliners, 33 advancers and 3 flat;
Monday closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.